1. Home
  2. TGE vs SCYX Comparison

TGE vs SCYX Comparison

Compare TGE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

BUY

Current Price

$0.67

Market Cap

46.3M

ML Signal

BUY

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.79

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
SCYX
Founded
2023
1999
Country
France
United States
Employees
166
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.3M
37.9M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TGE
SCYX
Price
$0.67
$3.79
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $36.33
AVG Volume (30 Days)
★ 509.1K
272.0K
Earning Date
09-30-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.36
EPS
★ N/A
N/A
Revenue
N/A
★ $257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$977.86
P/E Ratio
$2.99
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.66
52 Week High
$3.21
$6.09

Technical Indicators

Market Signals
Indicator
TGE
SCYX
Relative Strength Index (RSI) 34.87 36.17
Support Level N/A $3.75
Resistance Level $0.99 $4.30
Average True Range (ATR) 0.10 0.26
MACD -0.03 -0.04
Stochastic Oscillator 3.87 14.53

Price Performance

Historical Comparison
TGE
SCYX

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: